These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8033761)

  • 21. [Use of naltrexone in the treatment of young drug addicts].
    Waal H; Aamodt Ø; Olsen H
    Tidsskr Nor Laegeforen; 2003 Jun; 123(12):1662-4. PubMed ID: 12821983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts.
    Hensel M; Kox WJ
    Acta Anaesthesiol Scand; 2000 Mar; 44(3):326-33. PubMed ID: 10714849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Narcotic antagonists in drug dependence: pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy.
    Chen TJ; Blum K; Payte JT; Schoolfield J; Hopper D; Stanford M; Braverman ER
    Med Hypotheses; 2004; 63(3):538-48. PubMed ID: 15288384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three methods of opioid detoxification in a primary care setting. A randomized trial.
    O'Connor PG; Carroll KM; Shi JM; Schottenfeld RS; Kosten TR; Rounsaville BJ
    Ann Intern Med; 1997 Oct; 127(7):526-30. PubMed ID: 9313020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results.
    Cucchia AT; Monnat M; Spagnoli J; Ferrero F; Bertschy G
    Drug Alcohol Depend; 1998 Nov; 52(3):243-50. PubMed ID: 9839150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in naltrexone treatment compliance with contingency management.
    Preston KL; Silverman K; Umbricht A; DeJesus A; Montoya ID; Schuster CR
    Drug Alcohol Depend; 1999 Apr; 54(2):127-35. PubMed ID: 10217552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical experience with naltrexone in suburban opioid addicts.
    Tennant FS; Rawson RA; Cohen AJ; Mann A
    J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):42-5. PubMed ID: 6469935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels.
    Foster J; Brewer C; Steele T
    Addict Biol; 2003 Jun; 8(2):211-7. PubMed ID: 12850780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised, controlled trial of low dose naltrexone for the treatment of opioid dependence.
    Rea F; Bell JR; Young MR; Mattick RP
    Drug Alcohol Depend; 2004 Jul; 75(1):79-88. PubMed ID: 15225891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence.
    Kakko J; von Wachenfeldt J; Svanborg KD; Lidström J; Barr CS; Heilig M
    Biol Psychiatry; 2008 Jan; 63(2):172-7. PubMed ID: 17850768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland--Swiss national cohort study.
    Gschwend P; Rehm J; Blättler R; Steffen T; Seidenberg A; Christen S; Bürki C; Gutzwiller F
    Eur Addict Res; 2004; 10(1):41-8. PubMed ID: 14665805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic naltrexone suppresses platelet aggregation induced by adrenaline and 5-hydroxytryptamine in former heroin addicts.
    García-Sevilla JA; Ulibarri I; Giralt MT; Areso P; Oliveros RG; Gutiérrez M
    J Neural Transm; 1988; 73(2):157-60. PubMed ID: 3210007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success.
    Seoane A; Carrasco G; Cabré L; Puiggrós A; Hernández E; Alvarez M; Costa J; Molina R; Sobrepere G
    Br J Psychiatry; 1997 Oct; 171():340-5. PubMed ID: 9373422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Craving in heroin addicts maintained on the opiate antagonist naltrexone.
    Sideroff SI; Charuvastra VC; Jarvik ME
    Am J Drug Alcohol Abuse; 1978; 5(4):415-23. PubMed ID: 755381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of heroin-dependent persons with antagonists: current status.
    Renault PF
    NIDA Res Monogr; 1981; 28():11-22. PubMed ID: 6791000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Buprenorphine suppresses heroin use by heroin addicts.
    Mello NK; Mendelson JH
    Science; 1980 Feb; 207(4431):657-9. PubMed ID: 7352279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naltrexone in the treatment of opiate dependence.
    Resnick RB; Washton AM; Thomas MA; Kestenbaum RS
    NIDA Res Monogr; 1978; (19):321-32. PubMed ID: 218108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.